Skip to main content
Top
Published in: Clinical Orthopaedics and Related Research® 12/2016

01-12-2016 | CORR Insights

CORR Insights®: Is Botulinum Toxin Type A a Valuable Adjunct During Femoral Lengthening? A Randomized Trial

Author: Stuart A. Green, MD

Published in: Clinical Orthopaedics and Related Research® | Issue 12/2016

Login to get access

Excerpt

The history of medicine is replete with instances of failed extrapolations. Bloodletting, for instance, may have started when an ancient healer observed the beneficial effect of blood loss in cases of congestive heart failure. Extrapolating to all maladies resulted in two millennia of induced hypovolemia, anemia, and premature death. …
Literature
1.
go back to reference Moseley JB, O’Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, Ashton CM, Wray NP. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347:81–88.CrossRefPubMed Moseley JB, O’Malley K, Petersen NJ, Menke TJ, Brody BA, Kuykendall DH, Hollingsworth JC, Ashton CM, Wray NP. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med. 2002;347:81–88.CrossRefPubMed
Metadata
Title
CORR Insights®: Is Botulinum Toxin Type A a Valuable Adjunct During Femoral Lengthening? A Randomized Trial
Author
Stuart A. Green, MD
Publication date
01-12-2016
Publisher
Springer US
Published in
Clinical Orthopaedics and Related Research® / Issue 12/2016
Print ISSN: 0009-921X
Electronic ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-016-5082-y

Other articles of this Issue 12/2016

Clinical Orthopaedics and Related Research® 12/2016 Go to the issue